MedTrace Logo

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

NCT05903937 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-06-15

No results posted yet for this study

Summary

Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of malignant melanoma

Conditions

Interventions

DRUG

Autologous Tumor Infiltrating Lymphocytes

Administered via hepatic arterial infusion (HAI)

DRUG

Melphalan

Administered via isolated hepatic perfusion

DRUG

Interleukin-2

low-dose, administered s.c.

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-31
Primary Completion
2024-12-31
Completion
2029-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05903937 on ClinicalTrials.gov